Mohindru Mani purchased $50K of CRDF

Mohindru Mani (Chief Executive Officer) purchased 34,364 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 on 2026-07-14.

Original reporting
SEC EDGAR · Mohindru Mani
Published Jul 16, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRDF
Bullish
medium confidence
Mentioned
$CRDF
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRDFBullishLow
01

Why it matters

The newest fact is the CEO’s open-market purchase of 34,364 shares at $1.4550 on 2026-07-14, filed on 2026-07-16. This can slightly influence sentiment but does not introduce new company-specific fundamentals (no guidance, trial results, or financing terms).

02

Market read

Traders may note the CEO’s buy as a small positive signal, but it is unlikely to be a standalone catalyst without accompanying operational news.

03

What to watch

The filing does not mention a 10b5-1 plan, but it also provides no rationale for the purchase, and the price ($1.4550) may reflect prevailing market conditions rather than new information.

Relevance 4/10Novelty 5/10Timing: new SEC Form 4 filed 2026-07-16 for a 2026-07-14 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Cardiff Oncology, Inc. (CRDF) by CEO Mohindru Mani.

Company-level read

Ticker impact

$CRDFBullishMedium confidence
Context

SEC Form 4 shows CEO Mohindru Mani bought 34,364 shares of Cardiff Oncology at $1.4550 on 2026-07-14, totaling about $50k.

Expected impact

Near-term impact likely limited; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The disclosure is primary-source and time-stamped, but the transaction size is relatively small versus typical market-moving insider trades, and it provides no new operating or financial guidance.

Market effects

Limited read-across to the oncology biotech sector because the filing contains no clinical, regulatory, or financing updates.

None indicated; this is a US-listed company insider transaction.

Minimal; no global deal, trial, or regulatory action is described.

Counterpoint

Insider buys can be routine liquidity or diversification-related and do not necessarily signal improved near-term prospects, especially at modest dollar size.

Key entities

  • Cardiff Oncology, Inc.

    Subject of the Form 4 insider transaction disclosure (CRDF).

  • Mohindru Mani

    CEO and director who purchased 34,364 shares open-market for about $49,999.62.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRDFHighAI 9/10

Why is Cardiff Oncology stock surging today?

Cardiff Oncology (CRDF) stock rose 25% after FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data showing a 72.2% response rate. CEO Mani Mohindru is presenting at the UBS Global Biopharma Conference. The stock's surge contrasts with a broader market decline.

$CRDFMed

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in t

$CRDFMedAI 8/10

FDA grants orphan drug status to Cardiff’s onvansertib for CMML

Cardiff Oncology (CRDF) received FDA Orphan Drug Designation for onvansertib to treat chronic myelomonocytic leukemia (CMML). The drug showed preliminary efficacy in a Phase 1 trial, with benefits including platelet response and stable disease. Orphan Drug Designation offers tax credits, fee exemptions, and market exclusivity. CRDF is developing onvansertib for other cancers as well.

$CRDFMed

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m